NCT06783998|Enrolling By Invitation
Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome
RMS-OSAS
Loading search results
RMS-OSAS
Sponsor study identifier
observational
150
1 country
1
Study Start
May 15, 2025
Actual (reported)Primary Completion
February 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
April 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients. This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 6, 2025
Actual (reported)January 20, 2025
Actual (reported)May 15, 2025
Actual (reported)February 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Anthropometric measurement
Waist circumference, hip circumference will be measured, waist-hip ratio will be calculated.
1 year
BOdy mass measurement
Body weight,fat-free mass (FFM) and appendicular skeletal muscle mass (ASMM) and skeletal muscle mass expressed in kilograms will be measured by bioelectrical impedance.
1 year
Hand Grip strength
Jamar hand dynamometer, which is recommended by the American Association of Hand Therapists (AETD) and has been found to have high validity and reliability in many studies and is therefore considered the gold standard, will be used to measure hand grip strength.
1 year
Walking speed
Walking speed will be measured with the 4 Meter Walking Speed Test (4MYHT).
1 year
Respiratory muscle strength:
Respiratory muscle strength will be evaluated with a portable, electronic mouth pressure measurement device.
1 year
Functional capacity
1 year
Turkish-speaking patients diagnosed with normal-mild-moderate-severe OSAS, aged 18 and over, will be included.
Patients with normal-mild-medium-severe Obstructive Sleep Apnea Syndrome
Tarsus University
Mersin, Mersin, Turkey (Türkiye)
First Submitted
January 6, 2025
First Posted
January 20, 2025
Study Start
May 15, 2025
Actual (reported)Primary Completion
February 15, 2026
Estimated (date passed)A Prospective Randomnised Controlled Trial Comparing Overall Patient Compliance in a Bariatric Surgical Pathway Using the Standard Versus a More Intensified and Interactive Version of the "Get Ready" Smartphone Application.
Expiratory flow rate
Peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR) and peak flow measurement, will be measured with a PEFmeter (MSA 100 PEFmeter), a small, hand-held device used to monitor a person's ability to breathe air.
1 year
Respiratory function test
To evaluate pulmonary functions(FEV1/FVC ve FEV1 ), it will be measured in a sitting position with a Spirolab III brand spirometer according to ATS/European Respiratory Society (ERS) criteria.
1 year
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
April 15, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 28, 2025
Record last verified: 2025-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: